Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (4121) 4121
life sciences & biomedicine (3872) 3872
humans (2706) 2706
animals (2181) 2181
male (2103) 2103
endocrinology & metabolism (1787) 1787
glucagon (1638) 1638
diabetes (1551) 1551
diabetes mellitus, type 2 - drug therapy (1375) 1375
type 2 diabetes (1370) 1370
glucagon-like peptide 1 (1288) 1288
glucose (1162) 1162
peptides (1154) 1154
female (1140) 1140
insulin (1102) 1102
hypoglycemic agents - therapeutic use (963) 963
rats (833) 833
mice (831) 831
glucagon-like peptide-1 receptor (816) 816
diabetes mellitus (808) 808
biological and medical sciences (798) 798
glucagon-like peptide-1 (768) 768
middle aged (742) 742
glucagon-like peptide 1 - metabolism (708) 708
blood glucose - metabolism (706) 706
obesity (645) 645
pharmacology & pharmacy (640) 640
abridged index medicus (626) 626
adult (614) 614
glp-1 (597) 597
liraglutide (572) 572
medical sciences (571) 571
glucagon-like peptide 1 - analogs & derivatives (553) 553
dextrose (541) 541
rodents (535) 535
digestive, oral, and skin physiology (527) 527
hypoglycemic agents - administration & dosage (524) 524
glucagon-like peptide-1 receptor - agonists (523) 523
research (523) 523
analysis (516) 516
insulin - metabolism (508) 508
physiological aspects (506) 506
hypoglycemic agents - pharmacology (492) 492
insulin resistance (465) 465
diabetes mellitus, type 2 - blood (459) 459
insulin - blood (459) 459
endocrine system (458) 458
blood glucose - drug effects (457) 457
receptors, glucagon - agonists (445) 445
treatment outcome (439) 439
aged (433) 433
glucagon-like peptide 1 - therapeutic use (429) 429
diabetes mellitus, type 2 - metabolism (425) 425
internal medicine (425) 425
peptides - pharmacology (425) 425
glucagon-like peptide 1 - blood (422) 422
glucagon-like peptide 1 - pharmacology (420) 420
medicine & public health (413) 413
care and treatment (408) 408
hormones, hormone substitutes, and hormone antagonists (403) 403
hypoglycemic agents - adverse effects (402) 402
health aspects (396) 396
physiology (388) 388
body weight (385) 385
endocrinopathies (382) 382
exenatide (371) 371
hypoglycemic agents (371) 371
insulin secretion (370) 370
rats, sprague-dawley (370) 370
glucose metabolism (368) 368
metabolism (364) 364
mice, inbred c57bl (362) 362
endocrine pancreas. apud cells (354) 354
diabetes. impaired glucose tolerance (353) 353
fundamental and applied biological sciences. psychology (348) 348
diabetes therapy (339) 339
drug therapy (332) 332
risk factors (330) 330
etiopathogenesis. screening. investigations. target tissue resistance (328) 328
clinical trials (323) 323
peptides - therapeutic use (323) 323
glucagon-like peptide 1 - administration & dosage (322) 322
hyperglycemia (314) 314
venoms - pharmacology (311) 311
dipeptidyl-peptidase iv inhibitors - therapeutic use (310) 310
receptors, glucagon - metabolism (307) 307
glucose tolerance test (298) 298
hormones (280) 280
neurosciences (279) 279
glucagon-like peptide-1 receptor - metabolism (278) 278
proteins (270) 270
dose-response relationship, drug (269) 269
medicine (267) 267
peptides - administration & dosage (265) 265
endocrinology (262) 262
neurosciences & neurology (259) 259
venoms - therapeutic use (259) 259
biochemistry & molecular biology (255) 255
type 2 diabetes mellitus (253) 253
research & experimental medicine (247) 247
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4740) 4740
Japanese (16) 16
German (14) 14
French (6) 6
Spanish (6) 6
Portuguese (3) 3
Czech (2) 2
Russian (2) 2
Swedish (2) 2
Danish (1) 1
Dutch (1) 1
Italian (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
by Drucker, Daniel J and Nauck, Michael A
The Lancet (British edition), ISSN 0140-6736, 2006, Volume 368, Issue 9548, pp. 1696 - 1705
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | General aspects | Diabetes. Impaired glucose tolerance | Biological and medical sciences | Endocrinopathies | Etiopathogenesis. Screening. Investigations. Target tissue resistance | Medical sciences | Endocrine pancreas. Apud cells (diseases) | Triazoles - administration & dosage | Triazoles - adverse effects | Glucagon-Like Peptide 1 - administration & dosage | Humans | Pyrazines - administration & dosage | Glucagon-Like Peptide 1 - biosynthesis | Dipeptidyl Peptidase 4 | Glucagon-Like Peptide 1 - physiology | Pyrazines - therapeutic use | Adenosine Deaminase Inhibitors | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Adamantane - therapeutic use | Pyrrolidines | Venoms - administration & dosage | Nitriles | Sitagliptin Phosphate | Adamantane - administration & dosage | Adamantane - adverse effects | Adamantane - analogs & derivatives | Triazoles - therapeutic use | Glucagon-Like Peptide 1 - classification | Hypoglycemic Agents - therapeutic use | Receptors, Glucagon - agonists | Drug Administration Schedule | Glucagon-Like Peptide 1 - analogs & derivatives | Venoms - adverse effects | Glycoproteins - antagonists & inhibitors | Clinical Trials as Topic | Glucagon-Like Peptide-1 Receptor | Dipeptidyl-Peptidase IV Inhibitors | Pyrazines - adverse effects | Venoms - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypoglycemic Agents - adverse effects | Liraglutide | Peptides - adverse effects | Peptides - therapeutic use | Glucagon-Like Peptide 1 - therapeutic use | Type 2 diabetes | Care and treatment | Diagnosis | Glucagon | Analysis | Dosage and administration | Research | Protease inhibitors | Drug therapy | Proteins | Diabetes | Kinases | Insulin | Rodents | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2
by Tolhurst, Gwen and Heffron, Helen and Lam, Yu Shan and Parker, Helen E and Habib, Abdella M and Diakogiannaki, Eleftheria and Cameron, Jennifer and Grosse, Johannes and Reimann, Frank and Gribble, Fiona M
Diabetes (New York, N.Y.), ISSN 0012-1797, 02/2012, Volume 61, Issue 2, pp. 364 - 371
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Biological and medical sciences | Endocrinopathies | Etiopathogenesis. Screening. Investigations. Target tissue resistance | Diabetes. Impaired glucose tolerance | Medical sciences | Endocrine pancreas. Apud cells (diseases) | Fatty Acids, Volatile - pharmacology | Animals | Signal Transduction | Calcium - metabolism | Mice, Inbred C57BL | Colon - secretion | Mice | GTP-Binding Protein alpha Subunits, Gi-Go - physiology | Colon - metabolism | Glucagon-Like Peptide 1 - secretion | Receptors, G-Protein-Coupled - physiology | Physiological aspects | Cell receptors | Research | Peptides | Fatty acids | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments A Systematic Review and Network Meta-analysis
by Zaccardi, Francesco and Htike, Zin Zin and Webb, David R and Khunti, Kamlesh and Davies, Melanie J
Annals of internal medicine, ISSN 0003-4819, 01/2016, Volume 164, Issue 2, pp. 102 - 113
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hypoglycemic Agents - therapeutic use | Drug Administration Schedule | Nausea - chemically induced | Glycated Hemoglobin A - metabolism | Humans | Diabetes Mellitus, Type 2 - blood | Hypoglycemic Agents - administration & dosage | Weight Loss | Hemodynamics - drug effects | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemia - chemically induced | Hypoglycemic Agents - adverse effects | Glucagon-Like Peptide-1 Receptor - agonists | Hemoglobin | Heart beat | Research | Primary health care | Adults | Diabetes | Antagonist drugs | Weight | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain–Adipocyte Axis
by Geloneze, Bruno and de Lima-Júnior, José Carlos and Velloso, Lício A
Drugs (New York, N.Y.), ISSN 0012-6667, 4/2017, Volume 77, Issue 5, pp. 493 - 503
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Pharmacology & Pharmacy | Toxicology | Life Sciences & Biomedicine | Science & Technology | Brain - drug effects | Brain - metabolism | Glucagon-Like Peptide-1 Receptor - metabolism | Animals | Hypoglycemic Agents - administration & dosage | Adipocytes - metabolism | Humans | Adipocytes - drug effects | Diabetes Mellitus, Type 2 - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide-1 Receptor - agonists | Brain | Transcription | Peptides | Glucagon | Circuits | Arcuate nucleus | Parkinsons disease | Homeostasis | Clinical trials | Body weight loss | Hormones | Adipocytes | Hypothalamus | Glucose | Nuclei | Rodents | Hepatology | Nutrients | Physiology | Glucagon-like peptide 1 | Food | Neuropeptide Y | Obesity | Medical research | Diabetes mellitus | Weight loss | Energy expenditure | Metabolism | Insulin | Microglia | Energy balance | Neurotransmitters | Weight control | Gliosis | Amphetamine | Diet | Food intake | Neural networks | Leptin | Genesis | Cocaine- and amphetamine-regulated transcript protein | Cocaine | Diabetes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials
by Vilsbøll, Tina and Christensen, Mikkel and Junker, Anders E and Knop, Filip K and Gluud, Lise Lotte
BMJ, ISSN 0959-8138, 1/2012, Volume 344, Issue 7841, pp. 14 - 14
RESEARCH | Obesity | Receptors | Body weight | Weight loss | Agonists | Experimentation | Blood pressure | Type 2 diabetes mellitus | Cholesterols | Overweight | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hypoglycemic Agents - therapeutic use | Receptors, Glucagon - agonists | Overweight - complications | Drug Administration Schedule | Obesity - drug therapy | Glucagon-Like Peptide 1 - analogs & derivatives | Obesity - complications | Overweight - drug therapy | Humans | Glucagon-Like Peptide 1 - pharmacology | Treatment Outcome | Weight Loss - drug effects | Anti-Obesity Agents - therapeutic use | Hypoglycemic Agents - pharmacology | Peptides - pharmacology | Glucagon-Like Peptide-1 Receptor | Venoms - therapeutic use | Venoms - pharmacology | Diabetes Mellitus, Type 2 - drug therapy | Diabetes Mellitus, Type 2 - complications | Liraglutide | Peptides - therapeutic use | Glucagon-Like Peptide 1 - therapeutic use | Systematic review | Weight control | Diabetes | Peptides | Drug therapy | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect
by Sisley, Stephanie and Gutierrez-Aguilar, Ruth and Scott, Michael and D'Alessio, David A and Sandoval, Darleen A and Seeley, Randy J
The Journal of clinical investigation, ISSN 0021-9738, 06/2014, Volume 124, Issue 6, pp. 2456 - 2463
Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Receptors, Glucagon - genetics | Receptors, Glucagon - deficiency | Glucagon-Like Peptide 1 - analogs & derivatives | Appetite Depressants - pharmacology | Mice, Inbred C57BL | Glucagon-Like Peptide 1 - pharmacology | Body Weight - drug effects | Male | Peripheral Nerves - drug effects | Hypoglycemic Agents - pharmacology | Mice, Knockout | Central Nervous System - physiology | Eating - drug effects | Animals | Glucagon-Like Peptide-1 Receptor | Peripheral Nerves - physiology | Diet, High-Fat | Central Nervous System - drug effects | Mice | Liraglutide | Receptors, Glucagon - physiology | Measurement | Glucagon | Blood sugar | Physiological aspects | Dosage and administration | Gene expression | Health aspects | Proteins | Studies | Nervous system | Weight control | Rodents | Food | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Glucagon-like peptide-1 and its class B G Protein-coupled receptors: A long march to therapeutic successes
by de Graaf, C and Donnely, D and Wootten, D and Lau, J and Sexton, P.M and Miller, L.J and Ahn, J.M and Liao, J and Fletcher, M.M and Yang, D and Brown, A.J and Zhou, C and Deng, J and Wang, M.W
Pharmacological reviews, ISSN 0031-6997, 2016, Volume 68, Issue 4, pp. 954 - 1013
Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Animals | Glucagon-Like Peptide 1 - metabolism | Receptors, G-Protein-Coupled - metabolism | Humans | Glucagon-Like Peptide 1 - chemistry | Glucagon-Like Peptide 1 - genetics | Receptors, G-Protein-Coupled - chemistry | Index Medicus | Review
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights